Dr. Sergio L. Faria, MD, PhD

Claim this profile

McGill University Health Centre-Cedars Cancer Centre

Studies Prostate Cancer
Studies Lung Cancer
4 reported clinical trials
6 drugs studied

Affiliated Hospitals

Image of trial facility.
McGill University Health Centre-Cedars Cancer Centre
Image of trial facility.
McGill University Health Centre, Glen Site Cedars Cancer Center

Clinical Trials Sergio L. Faria, MD, PhD is currently running

Image of trial facility.

SBRT

for Prostate Cancer

It is a phase I study of radical hypofractionation delivering one single fraction of SBRT in patients with low- and favorable intermediate-risk prostate cancer that will undergo placement of the SpaceOAR hydrogel prior to treatment. Our hypothesis is that treatments can be safely delivered in one single fraction using SBRT provided the separation between the prostate and rectum is increased using the hydrogel
Recruiting1 award N/A6 criteria
Image of trial facility.

Hypofractionated Radiation Therapy + Eligard

for Prostate Cancer

Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk tumour characteristic. Although surgery can be curative in patients evidencing pathological high-risk disease (extracapsular extension, seminal vesicle involvement, positive surgical margins), a large proportion will develop biochemical failure within years from the surgical procedure. The failure rate is even more pronounced in those patients that present with high prostate specific antigen (PSA) levels, pT3 disease, positive margins and Gleason score ≥8 with an estimated 75% failure rate at 10 years. Post-operative radiotherapy (RT) has been shown in three randomized trials to significantly decrease the biochemical failure rate and in one of the trials a survival benefit was also seen with the addition of post-operative RT and is considered by many investigators standard therapy in patients with pathological high-risks factors even in absence of biochemical failure.
Recruiting2 awards Phase 210 criteria

More about Sergio L. Faria, MD, PhD

Clinical Trial Related7 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Sergio L. Faria, MD, PhD has experience with
  • SBRT
  • Eligard
  • Postop Hypofractionated Radiation Therapy
  • Chemoradiotherapy
  • Chemoradiotherapy With Integrated Boost Dose
  • Radical External Beam Radiotherapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Sergio L. Faria, MD, PhD specialize in?
Is Sergio L. Faria, MD, PhD currently recruiting for clinical trials?
Are there any treatments that Sergio L. Faria, MD, PhD has studied deeply?
What is the best way to schedule an appointment with Sergio L. Faria, MD, PhD?
What is the office address of Sergio L. Faria, MD, PhD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security